Enhancing Benefit With Durvalumab in NSCLC After the PACIFIC Trial
Dr. Bazhenova on the PACIFIC Trial With Durvalumab in NSCLCПодробнее
PACIFIC trial updates: durvalumab after chemotherapy in NSCLCПодробнее
Durvalumab Consolidation in NSCLC: The PACIFIC TrialПодробнее
PACIFIC: Progression-Free Survival Increase in NSCLCПодробнее
Treating for Stage III NSCLC After Progression on DurvalumabПодробнее
Post-hoc subgroup analysis from PACIFIC: durvalumab after CRT in unresectable stage III EGFRm NSCLCПодробнее
PACIFIC 6: durvalumab after sCRT in patients with NSCLCПодробнее
Locally advanced NSCLC: Combination therapy with targeted and immunotherapy agentsПодробнее
Examining Recent PACIFIC Trial Updates for Durvalumab in Locally Advanced NSCLCПодробнее
5-year survival outcomes from the PACIFIC trialПодробнее
Is Durvalumab Curing Patients or Just Treating Metastatic Disease Earlier? (BMIC-025)Подробнее
Refining which patients benefit from consolidation durvalumab for stage III unresectable NSCLCПодробнее
PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLCПодробнее
Results from the PACIFIC study: durvalumab with chemoradiation for the treatment of NSCLCПодробнее
Updated Results on PACIFIC Trial: Revise Who Should Receive Consolidation Immunotherapy? (BMIC-065)Подробнее
Locally Advanced NSCLC: Durvalumab and the PACIFIC TrialПодробнее
Dr. Langer on the Benefit of Durvalumab in Stage III NSCLCПодробнее
Reactions to the PACIFIC Trial in Stage III NSCLCПодробнее
Durvalumab (Imfinzi) FDA Approved for Stage III NSCLC: Standard of Care? (BMIC-024)Подробнее